| Literature DB >> 19559299 |
Katherine J Donnithorne1, T Prescott Atkinson, Claas H Hinze, Janaina B Nogueira, Shehzad A Saeed, David J Askenazi, Timothy Beukelman, Randy Q Cron.
Abstract
To report on the efficacy of rituximab (RTX) therapy in standard treatment-refractory, chronic Henoch-Schönlein purpura, a retrospective chart review of 3 pediatric patients treated with RTX for severe refractory chronic Henoch-Schönlein purpura was performed. All 3 patients responded to 1 or 2 courses of RTX without serious adverse events.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19559299 DOI： 10.1016/j.jpeds.2008.12.049
Source DB: PubMed Journal: J Pediatr ISSN： 0022-3476 Impact factor: 4.406